Podcasts about BCG

It's 2026. You're the CEO of a global bank or the Head of Surgery at a major hospital. An AI system looks at a complex set of volatile market data, or a patient's decade-long medical history, and gives you a directive. It doesn't just give you a percentage of probability. It tells you exactly what to do. But here is the catch: If that decision fails, "the machine told me so" won't hold up in court, in the boardroom, or at a patient's bedside. For a few years now, we've played a game of ‘black box' roulette, using AI that predicts the future based on the past. But in a world of sudden market shifts and unprecedented global change, the past is no longer a reliable map. We are entering the era of Automated Reasoning. This is the shift from AI that guesses to AI that proves. It's a market for explainable systems that is set to hit nearly ten billion dollars this year, doubling by 2032. Because today, leaders don't just need an answer; they need the logic behind it. They need a ‘glass box' they can trust. Scott Wiltamuth, Director of Software Development for Agentic AI and Automated Reasoning at AWS, alongside Mary Martin, Managing Director and Senior Partner at BCG and Varun Chitkara, Senior Vice President of Global Product & Technology at ADP join host Tom Parker. Sources: FT ResourcesThis content is paid for by AWS and is produced in partnership with the Financial Times' Commercial Department. The views and claims expressed are those of the guests alone and have not been independently verified by The Financial Times. Hosted on Acast. See acast.com/privacy for more information.

For this episode, let's revisit a strategy skills classic interview with the coauthor of the book Personalized: Customer Strategy in the Age of AI, Mark Abraham. In this episode, we explore the rise of personalization through digital tools and AI, and how companies and organizations are leveraging it to build connections and engage with their customers. We discuss companies that excel in this area, such as Starbucks with its personalization engine, and Spotify with its tailored music recommendations. Personalization is not just about data; it's also about responding effectively to customer insights, enhancing customer experiences, and driving growth. Mark Abraham is a senior partner at BCG and the founder of the firm's Personalization business, which he has built into a global team of more than 1,000 agile marketers, data scientists, engineers, and martech experts. He and his team have accelerated the personalization efforts of more than a hundred iconic brands (including Starbucks, The Home Depot, and Google) and built some of BCG's largest ventures and AI platforms, including Fabriq by BCG for personalization. Currently, Mark leads BCG's North American Marketing, Sales & Pricing practice and is reenergizing the growth and development of talent in what is one of the firm's largest regional practices. Get Mark's book here: https://shorturl.at/Qj6Ys Personalized: Customer Strategy in the Age of AI Claim your free gift: Free gift #1 McKinsey & BCG winning resume www.FIRMSconsulting.com/resumePDF Free gift #2 Breakthrough Decisions Guide with 25 AI Prompts www.FIRMSconsulting.com/decisions Free gift #3 Five Reasons Why People Ignore Somebody www.FIRMSconsulting.com/owntheroom Free gift #4 Access episode 1 from Build a Consulting Firm, Level 1 www.FIRMSconsulting.com/build Free gift #5 The Overall Approach used in well-managed strategy studies www.FIRMSconsulting.com/OverallApproach Free gift #6 Get a copy of Nine Leaders in Action, a book we co-authored with some of our clients: www.FIRMSconsulting.com/gift

Welcome to this episode of Oncology Brothers, where we dived into the latest advancements in GU malignancies! We welcomed esteemed guests Dr. Brian Rini and Dr. Thomas Powles, both GU medical oncologists and co-hosts of the Uromigos podcast.   In this episode, we discussed key studies presented at ASCO 2026 that are set to change clinical practice in prostate, kidney and bladder cancer, and recent FDA approvals in the GU space: PROTEUS:  trial comparing ADT monotherapy to apalutamide plus ADT in high-risk localized prostate cancer. We explored its findings, implications, and the ongoing debate surrounding its control arm. TALAPRO-3 Study: impact of PARP inhibitors combined with enzalutamide in metastatic castration-sensitive prostate cancer with homologous recombination repair (HRR) mutations. We discussed the nuances of HRR mutations and their clinical significance. CAPITELLO-281: insights into the recent approval of this AKT inhibitor for metastatic castration-sensitive prostate cancer with PTEN loss, based on the CAPItello-281 study. EV-302 update: combination of EV-pembrolizumab still maintains the doubling of survival benefit with longterm follow up. POTOMAC: durvalumab + BCG induction therapy for high-risk non-muscle invasive bladder cancer (NMIBC) could be a choice for a selected patient population. LITESPARK-022: The new approval of belzutifan with pembrolizumab in the adjuvant setting, discussing its efficacy and the importance of patient selection.   Listen us on: Spotify: https://open.spotify.com/show/31BXhY9FM4gPWG10WgE11o ' Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966   Follow us on social media: X/Twitter: https://twitter.com/oncbrothers ⁠Instagram: https://www.instagram.com/oncbrothers Website: https://oncbrothers.com/   Throughout the episode, we emphasized the importance of balancing treatment benefits with potential adverse events, as well as the need for shared decision-making in clinical practice. #GUOncology, #ASCO2026, #ProstateCancer, #BladderCancer, #RenalCellCarcinoma, #OncologyBrothers

McKinsey, BCG, experts militants... Qui sont ces conseillers payés à prix d'or qui influencent les décisions de l'État ? Entre conflits d'intérêts, factures délirantes et décisions stratégiques douteuses, découvrez les coulisses du pouvoir.

In diesem Deep Dive spricht Markus mit Alexander Sommer-Fein, Managing Partner der LZH Group und Co-Founder von Smash. Alexander hat bei BCG strukturiertes Denken gelernt, Hans-Peter Haselsteiners Family Office mitaufgebaut und Startups bei „2 Minuten 2 Millionen" begleitet. Heute entwickelt er mit LZH standardisierte Wohnimmobilien im DACH-Raum und baut mit Smash – gemeinsam mit Investor Dominik Thiem,Padel-Standorte, die mehr als nur Sport sein sollen: Orte für Begegnung und Community.Production: Hanna MoserMusik (Intro/Outro): www.sebastianegger.com

Enterprise XR hasn't disappeared, it has quietly moved into places where it saves time, reduces errors and changes how people work every day. On this episode of the AI XR Podcast, Charlie Fink and Rony Abovitz talk with Boston Consulting Group partner Kristi Woolsey, who leads BCG's immersive practice, about how XR plus AI is already being used for training, maintenance, onboarding, retail and architecture inside some of the world's most conservative organizations.Kristi shares a Swiss Rail project where field technicians wear lightweight AR glasses that recognize who they are and which train car they are standing in front of, pull the correct procedures from internal systems and use AI to turn thick manuals into simple task checklists.She explains how this leads to double-digit efficiency gains for both experienced and new workers, and how a small behavior design choice – automatic logging for headset users versus manual end-of-shift paperwork for everyone else – helped overcome skepticism on the front line. Drawing on her background as a physical-space architect, she also describes how VR and rapidly improving 3D tools are changing the way companies design stores, offices and buildings before anything physical is built.AI XR News you should know, Charlie and Rony cover Anthropic's massive new funding round and ethics turbulence, Chinese generative video tools like Seed Dance 2 and Kling that put TV-quality visuals in reach of “garage Spielbergs,” and Meta's reported seven million Ray-Ban and Oakley AI smart glasses sold – early signals of where wearable AI and XR are really headed.Key Moments01:03 – Anthropic's huge raise and what the ethics departure might signal05:08 – Seed Dance 2 and Kling showcase a new level of generative video08:35 – Meta's seven million smart glasses and the reality behind that number12:10 – Why wearable AI may be the real “last mile” of turning us into cyborgs15:28 – Inside the early metaverse tours Kristi and Rony built for enterprises20:27 – How BCG's VR onboarding keeps new hires engaged months before day one23:30 – Swiss Rail's AR and AI maintenance assistant and what it actually does on site27:05 – Designing XR systems that give value to both the business and frontline workers30:29 – Using VR as a lab for retail and workplace behavioral strategy33:06 – How AI-generated 3D models point toward “build every space digitally first”This episode shows how “metaverse” ideas have turned into practical tools: XR plus AI is cutting training times, improving maintenance quality and letting companies experiment with spaces before they exist. Kristi's examples make it clear that the real action is in careful workflow design, not flashy avatars.This episode is brought to you by Zappar, creators of Mattercraft, the leading visual development environment for building immersive 3D web experiences for mobile, headsets and desktop. https://mattercraft.io/Mattercraft combines the power of a game engine with the flexibility of the web and now includes an AI assistant that helps you design, code and debug in real time, right in your browser. To explore what's possible with AI-powered XR on the web, start building smarter with Mattercraft from Zappar.Listen to “Enterprise XR Meets AI: How Smart Glasses, Digital Twins and Holodecks Are Quietly Changing Work – Kristi Woolsey” on the AI XR Podcast and follow the show for new episodes every week. Hosted on Acast. See acast.com/privacy for more information.

Lots of bite-size updates in this episode. Capitello-281: capivasertib + abiraterone (+ prednisone + ADT) Adjuvant Belzutifan + Pemroblizumab is FDA approved Durvalumab approved with BCG for non-muscle invasive bladder cancer Insightful commentary: https://doi.org/10.1200/JCO-25-02670 Talquetamab + Durvaluamb - a new safety signal? Learning Oncology Companion: https://www.kelleycpharmd.com/learning-oncology-companion-oncopharm

Why does up to 10% of bladder cancer pathology change on expert review, and what does that mean for your intermediate and high-risk patients? In this episode of BackTable, Dr. Bogdana Schmidt interviews urologists Dr. Kristen Scarpato and Dr. Sunil Patel to explore the complexities of diagnosis and risk assessment in non–muscle invasive bladder cancer (NMIBC). They discuss the real-world challenges of pathology interpretation, risk-group assignment, evolving diagnostic tools, and the impact these factors have on treatment decisions and patient outcomes. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Johnson & Johnson. --- Timestamps00:00 - Introduction01:02 - Risk Stratification07:22 - Upstaging to High Risk10:06 - Calculators and Patient Education15:22 - Specific Tests Use Cases18:50 - Conflicting Biomarker Results21:36 - Adjunct Tests and Counseling24:03 - Recurrence After Chemo Next Steps27:01 - Escalation Deescalation Balance32:48 - Future Research Priorities35:43 - Biology Based Risk Stratification38:03 - Clinical Pearls and Wrap Up --- More about this episodeThe conversation highlights the heterogeneity of intermediate-risk disease, the role and importance of expert pathology over-reads, and the need to accurately document the risk category for ongoing care. They discuss selective use of urinary and genomic assays and how these tests fit alongside cystoscopy and blue light endoscopy. Practical treatment approaches are reviewed, including when to use intravesical gemcitabine or BCG, managing care during BCG shortages, and balancing escalation versus de-escalation of therapy. Additional topics include strategies for long-term surveillance, upper tract imaging, rising rates of bladder cancer in younger patients, and why thorough TURBT and strong patient-provider communication remain central to optimal management. --- Resources The Memorial Studyhttps://www.mskcc.org/cancer-care/clinical-trials/19-288 The BRIDGE Studyhttps://www.nejm.org/doi/full/10.1056/NEJMoa1501035 --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.► https://www.backtable.com/app

Ragnhild Ørstavik deler siste nytt fra andre vitenskapelige tidsskrifter. Forskere gjør fremskritt i utvikling av en vaksine mot andesvirus (1). Hvor stor er spredningsfaren av smittsomme sykdommer på store arrangementer (2, 3)? Bør pasienter med alvorlig brannskade få høydosebehandling med vitamin C (4, 5)? Og er det egentlig grunnlag for å anbefale kalsium og vitamin D for å forebygge fall og osteoporotiske brudd (6, 7)? Leger i Japan trekker seg stille unna de vakttunge fagene og går mot fag som plastisk kirurgi (8). Har politiske tiltak noen effekt mot overvekt og fedme hos barn og unge (9, 10)? Kan CRISPR-genredigering bistå i behandling av den sjeldne sykdommen hereditært angioødem (11)? Forskning tyder på at BCG-vaksinen kan redusere insulinbehovet hos pasienter med type 1-diabetes (12). Og til slutt en personlig tekst om å hjelpe pasienter rammet av opioidkrisen i USA (13). Se hele litteraturlista her: https://tidsskriftet.no/2026/06/podkast/redaktorens-hjorne-110-andesvirus-vitamin-c-og-brannskader-crispr Tilbakemeldinger kan sendes til stetoskopet@tidsskriftet.no. Stetoskopet produseres av Helena Heimer Rognstad, Caroline Ulvin Johansson, Are Brean, Ragnhild Ørstavik og Julie Didriksen ved Tidsskrift for Den norske legeforening. Ansvarlig redaktør er Are Brean.Jingle og lydteknikk: Moderne media Coverillustrasjon: Stephen Lee See omnystudio.com/listener for privacy information.

Industry 4.0 is moving beyond factory walls and into farms, forests, and fields.David Potere, a senior tech leader in BCG's Industrial Goods and Climate Change and Sustainability practices, explores AI's move into the outdoor world. Robotics and connected systems are changing how farming and other outdoor activities get done.You'll Learn:Outdoor automation requires AI systems that can operate with constant uncertainty.Leaders should rethink long-held operating models as AI and robotics reshape how physical work gets done.The most valuable AI systems may be the ones that simplify complexity rather than add more dashboards.Learn More:David Potere: https://www.linkedin.com/in/davidpotere/What 1,000 Farmers Told Us About Tech Adoption: https://on.bcg.com/4euA76VClimate-Smart Agriculture Needs a Better Yardstick: https://on.bcg.com/4ejIfH6David on the Climate Rising Podcast: https://podcasts.apple.com/us/podcast/david-potere-at-bcg-x-using-ai-satellites-in-climate/id1482781075?i=1000767537614AI Foundation Model for Extreme Weather: https://on.bcg.com/4vKiwyzChapters00:00 – How Will AI Impact Outdoor Industries?04:26 –The Challenges of Taking Tech Outside06:11– What Would a Farm That Thinks for Itself Look Like?08:27 – Is AI Rescuing Agriculture?10:55– Will AI Only Help Big Farms?14:39 – Who Owns the Data?16:16 – What Can Leaders Learn from the AI Outdoors?18:51 – Next Steps to Truly Benefit from AIThis podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

Send us Fan MailIsh Mawla ran a BCG case in front of a live audience. Real candidate, real pressure.The case: a solar company in an emerging market watching its revenue fall while the broader market keeps growing. Aditya has to figure out why – and what to do about it.Then Ish breaks down the whole thing – what Aditya did well and where he left points on the table.Here's what stood out:Why your framework can work against you – and the one thing most candidates build in that they shouldn'tHow to read an exhibit under time pressure without glossing over the math that's sitting right in front of youWhat it takes to brainstorm boldly when the ask is doubling revenue, not incremental growthCoaching:Want this kind of feedback on your own cases? Start with a free 15-minute call with Katie – she'll tell you where you stand and whether Black Belt is the right fitBlack Belt is how you get a dedicated advisor, a personalized prep plan, and coaching from experts like Ish who know what MBB is looking forResources:New to MC? Create a free account and get access to our Case Foundations course, market research, and job board – no credit card required.Free Consulting Prep Just Got a Whole Lot BetterCreate a free MC account for access to step-by-step learning pathways, a brand new case prep course, and more. Download the MC app to prep anywhere.Connect With Management ConsultedCreate a free MC account or download the MC app (Apple, Android) to start your prep todaySchedule a free 15min consultation with the MC TeamWatch the video version of the podcast on YouTubeFollow us on LinkedIn, Instagram, and TikTokJoin an upcoming live event – case interviews demos, expert panels, and more

Cologne Major reached playoffs: talking through the biggest stories so far (and to come!) with Monte's coach kakafu in live-with-audience special from SK Gaming headquarters in Cologne, Germany. ➡️ Follow us for updates: https://twitter.com/HLTVconfirmed

88% of project schedules don't follow best practice. So why are we so keen to feed that data into AI and trust the output?In this episode, Dale and Val are joined by Michael Pink, Founder of SmartPM, for a sharp conversation on the forensic side of delay and the state of AI in project controls.Mike has analysed hundreds of thousands of schedules and built a career on working out who delayed what, and why nobody could ever agree. His core message: clean data is not the same as honest data. A technically tidy schedule can tell you a story that never happened, and if you point AI at it, you don't get insight, you get a confident wrong answer at scale.What we cover:Mike's route into construction, from a study-abroad debt to KPMG's construction consulting group25 years of change in the people and process side of schedulingThe shift from reactive forensic work to proactive project controlsData honesty vs data quality, and why integrity is the combination of both (framing credited to Isaac Dyer and Carlos Sanchez)The 88% problem: missing logic, inflated float and moving datesThe compression factor, and the exact point a schedule becomes infeasibleWhy a weekly update beats a monthly one, for almost no extra timeP6 vs Microsoft Project, and grading schedule quality across 35 metricsWhere LLMs genuinely help, and why quantitative AI is still the long gameThe future of the scheduler: less building and cleaning, more strategyA genuinely optimistic look at where the profession is heading, and why this might be the best time yet to be in project controls.This episode is proudly sponsored by nPlan.nPlan Summer AI Day 2026: Construction Superintelligence takes place in London on Thursday 25 June 2026, with a fireside featuring Peter Hancock, Project Director at National Grid, and Dima Pogorelsky, MD and Partner at BCG. February's event sold out with standing room only. Register here:https://www.nplan.io/events/nplan-summer-ai-day-2026-construction-superintelligenceConnect with Michael Pink at https://www.smartpm.com or on LinkedIn.If you enjoyed this episode, help us pay it forward and share it. Stay safe, be disruptive, and have fun doing it.

Retro-Episode - Die unterschätzte Zukunftskompetenz: AchtsamkeitDiese Folge ist ursprünglich 2021 erschienen. Und trotzdem passt sie heute fast noch besser als damals. Denn die Frage ist geblieben: Wie arbeiten wir eigentlich in einer Welt, in der Teams verteilter, Meetings dichter, Informationen schneller und Aufmerksamkeit knapper geworden sind? Robin und Patrick sprechen in dieser Plaudertaschen-Retro-Folge mit Jan Philipp Martini. Zum Zeitpunkt der Aufnahme war Jan Philipp Unternehmensberater bei BCG mit Schwerpunkt auf New Work und agile Transformation sowie Mitbegründer der Mindfulness Community bei BCG. Heute ist Jan Philipp sehr erfolgreicher Gründer von Sapiens (https://www.be-sapiens.com). Dort geht es um Health & Performance, also darum, Stressbelastung messbar zu machen und daraus konkrete Routinen für Gesundheit, Resilienz und Leistungsfähigkeit abzuleiten. Damit bekommt die Folge aus heutiger Sicht noch einmal eine zusätzliche Relevanz. Was damals als Gespräch über Mindfulness, New Work und bessere Zusammenarbeit begann, ist heute eine sehr konkrete Frage für viele Organisationen: Wie bleiben Menschen in anspruchsvollen Arbeitsumfeldern klar, präsent und leistungsfähig? Viel Spaß beim Hören! Fragen, Anregungen und Feedback sehr gerne an mail@plaudertaschen-podcast.de Euer Plaudertaschen-Team Dieser Podcast wird präsentiert von: => Sparkassen Personalberatung - Top-Talente finden, statt lange suchen => S Broker AG & Co. KG - Innovative und bedarfsorientierte Lösungen „as a Service“ für das Wertpapiergeschäft der Sparkassen. => Sparkassen Consulting GmbH - Wir. Beraten. Sparkassen. Folge direkt herunterladen

Send us Fan Mail5 people just landed offers at McKinsey, Bain, BCG, Deloitte, and L.E.K. We got them all in one room and asked them the same question: what actually worked?The real stuff – how many cases they did, how they networked, what they wish they'd done differently, and the misconceptions that almost cost them.Aisha did 50 cases her first recruiting cycle and didn't get the offer. She did 25 the second time and got it. That contrast says more than any framework guide will.You'll learn:Why quality beats volume in case prep – and what "quality" actually looks likeHow each of these 5 built their firm lists and network from scratchThe misconception every candidate walked in with (and when they figured out it was wrong)Resources:4 of the 5 panelists worked with an MC coach – learn more about Black Belt coachingNot sure if coaching is the right fit? Book a free 15-min call with Katie – she'll tell you where you standCreate a free MC account to start building your case prep foundationFree Consulting Prep Just Got a Whole Lot BetterCreate a free MC account for access to step-by-step learning pathways, a brand new case prep course, and more. Download the MC app to prep anywhere.Connect With Management ConsultedCreate a free MC account or download the MC app (Apple, Android) to start your prep todaySchedule a free 15min consultation with the MC TeamWatch the video version of the podcast on YouTubeFollow us on LinkedIn, Instagram, and TikTokJoin an upcoming live event – case interviews demos, expert panels, and more

What matters most to patients with non-muscle invasive bladder cancer (NMIBC)? In this episode of BackTable Urology, Dr. Kelly Bree, Dr. Saum Ghodoussipour, and Meredith Donahue, N.P., join host Dr. Vignesh Packiam to discuss the power of shared decision-making across the NMIBC spectrum. They explore risk-adapted treatment selection, when to escalate or de-escalate therapy, and how to navigate conversations about recurrence risk, treatment burden, quality of life, and the possibility of cystectomy. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by an educational grant from Johnson & Johnson. --- Timestamps 00:00 - Introduction01:55 - Second Opinions and Patient Counseling06:08 - Intermediate Risk Stratification12:13 - Treatment Options for Intermediate Risk NMIBC16:20 - BCG and Alternative Treatments for High Risk NMIBC26:49 - Options for BCG-Unresponsive NMIBC31:42 - Sequencing and Cystectomy37:03 - Financial and Time Toxicity41:08 - Biomarkers and ctDNA44:04 - Future Trials and NMIBC Innovations --- More about this episode They also review emerging therapies such as ZUSDURI, the evolving role of intravesical treatments, and the promise of biomarkers and ctDNA for personalized care. The discussion covers practical strategies for patient counseling, key updates to clinical guidelines, and a preview of innovations shaping the future of NMIBC management. --- Resources Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial:https://pubmed.ncbi.nlm.nih.gov/41571573/ Twelve-Month Results From the CISTO Study Comparing Radical Cystectomy Versus Bladder-Sparing Therapy for Recurrent High-Grade Non–Muscle-Invasive Bladder Cancerhttps://ascopubs.org/doi/10.1200/JCO-25-01324 CIRCULATING TUMOR DNA AS A BIOMARKER FOR UPSTAGING AND ADVERSE PATHOLOGY IN HIGH-RISK NON–MUSCLE-INVASIVE BLADDER CANCER:https://www.auajournals.org/doi/abs/10.1097/01.JU.0001191388.74345.c9.09 Preoperative Circulating Tumor DNA Predicts Upstaging and Recurrence in High-Risk Nonmuscle-Invasive Bladder Cancer Undergoing Radical Cystectomyhttps://pubmed.ncbi.nlm.nih.gov/41843048/ --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Top of his MBA class at the University of Bath, technically sharp, and still firing out 20 to 30 applications a day with little to show for it. Nick Chizuka joins Dale and Val for an honest conversation about what it takes to land a role in project controls and consulting right now, and why the rise of AI has made the graduate market tougher than it was even a year ago.It is a candid look at the gap between what universities teach and what employers actually want, the false choice between technical and soft skills, and where the real jobs of the next decade might come from.In this episode:Why a top MBA no longer guarantees a job, and what changedTechnical skills vs soft skills, and why you need bothThe graduates' verdict on data, analytics and machine learningRobotics and physical AI as the next frontierThe energy and infrastructure bottleneck nobody talks aboutUsing the big firms as a springboard, not a destinationGrit, discipline, and hiring for attitude over CVNick's hard-won advice: don't get discouraged, get help, and network relentlesslyA reminder that people are not their behaviours. Set the environment for success and the right person will fly.This episode is sponsored by nPlan.nPlan AI Day, Summer 2026: Construction SuperintelligenceThursday 25 June 2026, from 3:00pmKachette, 347 Old St, London EC1V 9LP, and onlinenPlan's twice-yearly showcase returns with its biggest product moment of the year, including the launch of the nPlan Decision Intelligence Platform. The fireside brings together Peter Hancock, Project Director at National Grid on the Didcot substation, and Dima Pogorelsky, Managing Director and Partner at BCG, for a candid take on delivering the infrastructure behind the AI era. February sold out with standing room only, so book early.Register: https://www.nplan.io/events/nplan-summer-ai-day-2026-construction-superintelligenceListen, subscribe and follow Project Chatter wherever you get your podcasts. If you enjoyed this one, pay it forward and share the link.Stay safe, be disruptive, and have fun doing it.

Confused about vaccinations in the Netherlands? You're not alone — it's one of the most asked questions in every expat parenting group. This week I'm joined by Youth Healthcare physician Dr. Marenne van Hengel Budde for a complete, plain-English guide to the Dutch vaccination system — from pregnancy through to age 14, and everything in between.We cover the full Dutch National Immunisation Programme (RVP), why chickenpox isn't on the Dutch schedule, the BCG tuberculosis vaccination that surprises many international families, meningitis B, travel vaccinations, and how to check your child's vaccination record online in minutes.IN THIS EPISODE: The Dutch National Immunisation Programme — who runs it, how it works, and why your GP is probably not involved Every vaccine on the schedule — from the whooping cough vaccine in pregnancy to the HPV vaccine at age 9, including the new RSV antibody (September 2025) and rotavirus vaccine (added 2024) Chickenpox — why it's not in the Dutch programme, what to do if you want it privately, and why age 12 matters BCG tuberculosis vaccine — who receives it, how the automatic invitation works, and what to expect from the skin reaction Meningitis B — why it's not included in the Dutch programme and how to access it privately (and what it costs) Travel vaccinations with babies and young children — where to go and how far in advance to plan How to check your child's full vaccination record online at mijn.rivm.nl — in under 2 minutes Missed a vaccination window? Here's what actually happens (it's probably not as bad as you think) Arriving from abroad with an existing vaccination schedule — do you have to start again? No. Here's how it works.ALL LINKS AND RESOURCES:

Arun Chauhan is an expert in investigations and fraud-based litigation in London. His company, Tenet Law, is a major disruptor in the field of fraud investigation and litigation, and as part of our ongoing innovation series, we wanted to find out from him how and why his firm is so successful. Today on the podcast we cover: The limits of employee trust as a compliance tool Arun's idea of a cutting-edge compliance playbook, And why NGOS and not for profits are uniquely at risk for financial crime. About the Show:Hosted by Hanjo Seibert, a leading expert in compliance, anti-financial crime and fraud, BCG on Compliance features interviews with heavy-hitters propelling compliance to the forefront of the industry. From crime prevention gurus to ethics champions, we'll ask provocative questions and bring you rich insights from the global players shaping the future of compliance, all in a dynamic and compact 20-minute episode.Whether you're a seasoned pro or new to the field, BCG on Compliance is your quick, comprehensive guide. Join us as we explore the profound ways compliance is altering industries around the globe. And connect with us at bcgoncompliance@bcg.comNew episodes are released monthly. You can also find BCG on Compliance on YouTubeResearch LinksHanjo Seibert LinkedInBCG LinkedInBCG websitewww.tenetlaw.co.uk

We Like Shooting - Ep 666 This episode of We Like Shooting is brought to you by: Foxtrot Mike (Code: WLSISLIFE) C&G Holsters (Code: WLSISLIFE) Midwest Industries (Code: WLSISLIFE) Gideon Optics (Code: WLSISLIFE) Flatline Fiber Co (Code: WLS15) Otis Technology (Code: WELIKESHOOTING15) Second Call Defense Text Dear WLS or Reviews +1 743 500 2171 Public   Show Titles   GOA GOALS Aug 1-2 in Iowa. https://goals.goa.org/ JUNE 20th, 2026 GunCon.net Tickets on sale now. Use code AGENCY171 GEAR CHAT Note Mike 102 – foxtrot mike products CANCONTRAST(Nick) CanContrast Suppressor Comparison Tool Choose a can CanContrast is an online database and interactive comparison tool for suppressors (“cans”). It enables users to select, compare, and contrast the physical size and weight of over 500 suppressor models from dozens of brands, with automatic adjustments for mounts. The site emphasizes data-only with no sales, featuring visual representations such as ruler overlays or weight bars. TRIGGER KICKER – HOFFMAN TACTICAL Hoffman Tactical Trigger Kicker Investigating some site issues, will restock in the morning. The Trigger Kicker is an active reset mechanism that replaces the disconnector in a standard AR-15 fire control group. It is contacted by the hammer to reset the trigger, then tucks under the standard safety selector to lock the trigger in the reset position until the bolt carrier returns to battery. Manufactured from hardened 4130 alloy steel, it is designed for AR-15 rifles with standard mil-spec bolt carriers and fire control groups. BULLET POINTS GUN FIGHTS Play the best Price Is Right-style GunBroker game on the internet. BANGRANK A live cast ranking segment for anything and everything in the gun world, powered by questionable certainty, strong opinions, and audience voting. THE AGENCY BRIEF WLS IS LIFESTYLE Masters of the Universe Masters of the Universe ODYSEE NVG Mono PVS-14 Hat Clip Adapter by stankycheeseman Lets you clip a PVS-14 or similar monocular to a hat. How neat is that?? It's going to be as sturdy as the hat you select for the job. Mount is pretty solid. Peep the readme. This is a 3D-printable CAD model (available as STEP files) for a hat clip adapter designed to mount a PVS-14 night vision monocular directly to a hat or cap. It includes components such as an IPD Knuckle and J Arm for compatibility with standard PVS-14 mounting interfaces. The design enables a lightweight, non-helmet alternative for monocular NVG use. GOING BALLISTIC PEW REPORT(Savage) Aero Precision, LLC and Ballistic Advantage, LLC Court-Appointed Receivership (Pierce County Superior Court Case No. 26-2-08316-4) Aero Precision and Ballistic Advantage Enter Court-Appointed Receivership Aero Precision and Ballistic Advantage are now under court-appointed receivership following an order entered in Pierce County Superior Court in Washington State on May 5, 2026. According to a public legal notice published in the Tacoma Daily Index, the court appointed J.S. Held LLC as receiver over […] On May 5, 2026, Pierce County Superior Court in Washington State appointed J.S. Held LLC as general receiver over the assets of Aero Precision, LLC (Lakewood, WA) and Ballistic Advantage, LLC (Ocoee, FL). Creditors must submit claims to the receiver; it is currently unclear whether assets will be available for distribution to general unsecured creditors. The public notice does not disclose the underlying causes or petitioner, and no filings indicate the companies have ceased operations. AMMOLAND SHOOTING SPORTS NEWS(Savage) Wilson v. Katz: Lynchburg Circuit Court Judge Patrick Yeatts Reaffirms Injunction Blocking Virginia HB 1525 Universal Background Checks A Lynchburg judge rejected Virginia's attempt to revive universal background checks on private firearm sales, keeping the injunction against State Police enforcement in place. On June 3, 2026, Lynchburg Circuit Court Judge Patrick Yeatts denied the Virginia State Police and Attorney General's motion to dissolve his October 2025 permanent injunction. The injunction struck down Virginia's universal background check requirement for private firearm sales (originally enacted in 2020 and codified at Va. Code § 18.2-308.2:5) after finding it unconstitutional under Article I, Section 13 of the Virginia Constitution, particularly as applied to those under 21, and non-severable. The ruling came after the legislature passed and Gov. Abigail Spanberger signed HB 1525 in April 2026 with an emergency clause directing VSP to resume checks; plaintiffs including Gun Owners of America, Virginia Citizens Defense League, and individuals filed to enforce the existing injunction. YouTube DOES RAREBREED HAVE A GOVERNMENT SANCTIONED MONOPOLY?(Savage) Rare Breed Triggers v. DOJ Settlement and ATF Director Robert Cekada Congressional Testimony on Forced Reset Triggers YouTubeVideo | Does RareBreed Have a Government Sanctioned Monopoly? Today we are going to be discussing the most recent development in the RareBreed Triggers situation. Since the settlement with the Department of Justice there have been many lawsuits filed and a major discussion about the legality of other devices that are similar to the FRT-15. Recently the new director of the ATF, Robert Cekada, testified in front of congress and had some interesting things to say about Forced Reset Triggers. ALL LINKS, Join the Email List, and get discounts from the affiliates page: https://linktr.ee/vso_gun_channel #vsogunchannel #rarebreeds #atf #gunlaw #MONOPOLY The VSO Gun Channel video in the Going Ballistic series examines the DOJ settlement with Rare Breed Triggers allowing continued FRT-15 sales contingent on patent enforcement, alongside recent congressional testimony by the new ATF director (referred to as Robert Cekada or Sacuta in sources) clarifying the settlement's narrow scope to Rare Breed's specific forced reset trigger design rather than all similar devices. The discussion covers legal distinctions between rate of fire, trigger function, drop-in auto sears, and potential implications for competing forced reset trigger products. AMMOLAND SHOOTING SPORTS NEWS(Savage) United States v. DeBorba (9th Cir. 2026): Suppressors Not Protected as 'Arms' Under Second Amendment The Ninth Circuit ruled suppressors are not Second Amendment arms in United States v. DeBorba, a bad-facts illegal alien gun case that may hurt future suppressor challenges. The Ninth Circuit affirmed João Ricardo DeBorba's convictions for unlawful possession of firearms, ammunition, and an unregistered silencer under the National Firearms Act (NFA). The court held that silencers/suppressors are optional accessories or ‘accoutrements' rather than ‘arms' covered by the plain text of the Second Amendment, citing prior precedent such as Duncan v. Bonta. It further ruled the NFA's shall-issue registration and taxation regime is constitutional as DeBorba failed to show abusive enforcement. NRA BLOWS WHISTLE ON NRA FOUNDATION, FILES LAWSUIT IN COURT(Savage) National Rifle Association of America v. NRA Foundation (1:26-cv-00015, D.D.C.) The National Rifle Association filed a lawsuit against the NRA Foundation, asserting ownership of intellectual property and alleging the foundation's leadership is operating in bad faith and withholding funds. NRA CEO Doug Hamlin stated the foundation has declined to approve 2026 grant funding, jeopardizing programs like the NRA National Firearms Museum and Eddie Eagle GunSafe program. On January 5, 2026, the National Rifle Association filed suit in U.S. District Court for the District of Columbia against its affiliated charitable arm, the NRA Foundation. The complaint asserts NRA ownership of trademarks and intellectual property used by the Foundation, alleges the Foundation's leadership (described as a disgruntled faction of former NRA directors) is operating in bad faith, misleading donors, withholding or misappropriating funds intended for NRA charitable programs, and attempting to break away. The suit seeks to prevent trademark infringement, unfair competition, and separation from the NRA. REVIEWS by Listener What's frustrating you most in gun culture right now? Review: Roadrunner gunner If you haver ever heard the phrase “hes got a face for radio.” Refering to someone who is ugly. Then Savage has the charisma to stand in a field like steel fucking gong. He means well but jesus christ, im a grown man with a stutter, but everytime he reads the news, i catch myself saying “T -T- T – today jr!” I never thought id say it but i wish AAron would come back, just to read the news even he couldn'tfuck that one up. Anyways the rest of you are sufficient enough that i dont regret being in the agency/cult or whatever it is now. Thanks for tickling my ear pu$$y twice a week. Review: Kyle R. from Iowa Dear WLS,Question I'm turning into a product review because I'm glad to hear about Foxtrot Mike signing on. What is the oddest, or most expensive fix you've ever done to get a trash gun running? For yourself, friend, customer, anyone. I got a Turkish 410 AR upper to play around with. Put it on a known functioning lower with their supplied modified buffer because the proprietary BCG is slightly longer. Slam fired half a magazine. Looked it over, tried a different lower with their other buffer they supplied. Slam fired 3 rounds, had an out of battery, sheared the bolt off. Sent it back. They sent me a whole new upper right around the same time I listened to the last episode you had Foxtrot Mike on. They were talking about slam firing 9mm and buffer weights. I immediately picked up a couple recoil mitigation buffers for PCCs. When the new 410 upper showed up I weighed the supplied buffers to

Aspiring NBA stars make a classic mistake when trying to watch, analyze and replicate the reasons why someone like Michael Jordan was so successful. In this podcast I explain why aspiring management consultants and those in industry make the very same mistake when watching, analyzing and replicating the reasons why McKinsey and BCG are so successful. Here are some free gifts for you: Overall Approach Used in Well-Managed Strategy Studies free download: www.firmsconsulting.com/OverallApproach McKinsey & BCG winning resume free download: www.firmsconsulting.com/resumepdf Enjoying this episode? Get access to sample advanced training episodes here: www.firmsconsulting.com/promo

I episode #130 prater jeg med Petter Haga; kjent for blant annet Mango IPA, Finance Daddy og flere humorprosjekter som har truffet bredt i Norge.Men bak virale videoer, låter og karakterer ligger det også en veldig interessant reise. Petter gikk Indøk på NTNU, var på vei inn i BCG-sporet, startet selskap, lagde musikk på siden - og endte etter hvert med å bygge en hverdag rundt humor, innhold, konferansierjobber, gründerskap og kreative prosjekter.I episoden snakker vi blant annet om:Hvordan Finance Daddy ble tilHvorfor Mango IPA ikke var en overnight successJanteloven, LinkedIn-kultur og det å tørre å være litt useriøsHvordan Petter tenker rundt sosiale medier, timing, volum og det å skape flaksPerioden etter startupen hvor han følte seg lost - og hvordan toastmaster-jobber ble starten på underholdningskarrierenHvordan Visning.ai ble bygget for å gjøre boligkjøp litt mindre kaotiskHvorfor humor, business og distribusjon kan være en ekstremt sterk kombinasjonEpisoden ble spilt inn tidligere i år, før Finance Daddy hadde vokst enda mer, men samtalen føles nesten enda mer relevant nå.En episode om humor, business, kreativitet - og hvorfor man noen ganger må lage utrolig mye før man plutselig treffer.Du kan finner mer om Petter og artistnavnet hans, Slamdunk her: SpotifyInstagramLinkedInDette er episode #130 med Petter Haga!

AI isn't replacing jobs the way headlines suggest, but it is changing who keeps them.Greg Emerson, BCG's global leader of technology and AI investing, explains why AI will reshape three to four times more jobs than it replaces. He argues that fears of mass unemployment are overblown and the real challenge for leaders is redesigning roles, workflows, and mindsets.You'll Learn:The real risk: workers who don't adopt AI will be replaced by those who do.How top performers will get more work, not less.Why leaders must move beyond tool adoption and fully reshape how work gets done.Learn More:Greg Emerson: https://on.bcg.com/43yhARMAI Will Reshape More Jobs Than It Replaces: https://on.bcg.com/4uxhTs5BCG's Latest Thinking on AI: https://on.bcg.com/4wWwHC9Latest Thinking from the BCG Institute: https://on.bcg.com/4fdjG0IWatch The So What on YouTube: https://www.youtube.com/playlist?list=PLMJgyXjV5gMI9JV-GcF_D1Y6zyf1Eab_0Chapters(0:00) AI Panic vs Reality(1:01) Is AI Replacement Imminent?(2:14) Where Are the Mass Unemployment Headlines Coming From?(4:28) Are AI Layoffs Really About AI?(7:51) AI Will Reshape More Jobs Than It Replaces(10:00) AI Is Creating More Work, Not Less(12:57) The Difference Between Replacing Jobs & Replacing People(14:47) The “Soft Resistance” Problem Inside Companies(16:00) The Biggest Career Risk Right Now(17:08) Why Businesses Struggle to Deliver AI ROI(19:05) The AI Adoption Trap(20:58) The AI Mindset Every Leader NeedsThis podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

Send us Fan MailWalter applied to consulting out of undergrad and didn't get an offer. Went into investment banking, got another shot a year and a half later, and still wasn't ready – too busy, not focused enough, cramming at the last minute.So he quit his job to recruit full time.That's an extreme version of the lesson, but the lesson applies to anyone working full time while trying to break in: you have less time than you think. Consulting firms aren't running a six-month hiring cycle. They've got a project to staff and they need someone now. You could apply today and interview next week.In this episode of Recruiting Reality Check, Katie Neff, ex-BCG and MC's Black Belt Advisor, breaks down what Walter did differently on attempt #3 – how he started from scratch, built a serious plan, and landed a full-time offer with L.E.K.The June Black Belt cohort closes Tuesday, June 9 (limited spots). Learn more and join.Resources:Book a free 15-minute call with Katie to map out your best pathJoin the June Black Belt cohort for structured coaching from application to offerExplore 2,000 consulting jobs for working professionals on the Management Consulted Job BoardConnect With Management ConsultedCreate a free MC account or download the MC app (Apple, Android) to start your prep todaySchedule a free 15min consultation with the MC TeamWatch the video version of the podcast on YouTubeFollow us on LinkedIn, Instagram, and TikTokJoin an upcoming live event – case interviews demos, expert panels, and more

In today's episode, we'll share a special podcast where our host Hanjo Seibert joins Marit Rødevand for an appearance on “The Laundry”, a podcast that highlights anti-money laundering practices, compliance and the ever-evolving world of financial crime. Hanjo's there to answer a simple question. Who Owns AI in Compliance? About The Laundry: The Laundry explores the complex world of financial crime, anti-money laundering (AML), compliance, sanctions, and global financial regulation.Hosted by Marit Rødevand, Fredrik Riiser, and Robin Lycka, each episode features in-depth conversations with leading experts from banking, fintech, regulatory bodies, and investigative journalism, dissecting headline news, unpacking regulatory trends, and examining the real-world consequences of non-compliance.The Laundry is proudly produced by Strise.Get in touch: laundry@strise.aiSubscribe to our newsletter, Fresh Laundry, here.Hosted on Acast. See acast.com/privacy for more information.BCG on Compliance: Hosted by Hanjo Seibert, a leading expert in compliance, anti-financial crime and fraud, BCG on Compliance features interviews with heavy-hitters propelling compliance to the forefront of the industry. From crime prevention gurus to ethics champions, we'll ask provocative questions and bring you rich insights from the global players shaping the future of compliance, all in a dynamic and compact 20-minute episode.Whether you're a seasoned pro or new to the field, BCG on Compliance is your quick, comprehensive guide. Join us as we explore the profound ways compliance is altering industries around the globe. And connect with us at bcgoncompliance@bcg.com

Ready to move beyond “one-size-fits-all” for BCG-unresponsive NMIBC? In this episode of BackTable Urology, Dr. Ruchika Talwar hosts Dr. Sam Chang to discuss the evolving treatment landscape for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). They explore why BCG may fail, the science and clinical rationale behind new immunotherapies and gene therapies, practical approaches to patient selection, treatment sequencing, and surveillance, and the value of emerging biomarkers, empowering urologists to make more informed, personalized decisions in complex cases of NMIBC. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by ImmunityBiohttps://anktiva.com/ --- Timestamps 00:00 - Introduction03:48 - BCG: How it Works and Why it Fails11:13 - Pembrolizumab Role and Limits14:38 - Nadofaragene firadenovec 16:34 - Cretostimogene grenadenorepvec18:39 - BCG + Anktiva Rationale29:50 - Explaining Options to Patients33:05 - Post Treatment Surveillance37:32 - Future of Biomarkers and AI42:05 - Key Takeaways --- Resources N-803 Plus BCG Treatment for BCG-Naïve or -Unresponsive Non-Muscle Invasive Bladder Cancer: A Plain Language Reviewhttps://pmc.ncbi.nlm.nih.gov/articles/PMC11524197/ Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guérin (BCG) for the Treatment of Bladder Cancerhttps://doi.org/10.1080/2162402X.2021.1912885 IL-15 Superagonist NAI in BCG-Unresponsive Non–Muscle-Invasive Bladder Cancerhttps://evidence.nejm.org/doi/full/10.1056/EVIDoa2200167 --- More about this episode This podcast is for informational purposes only. The views and opinions expressed in this podcast are solely those of the moderator and individual guest. --- BackTable Urology is the go-to podcast for urologists, urologic oncologists, and urogynecologists. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll explore a landscape teeming with strategic partnerships, groundbreaking clinical trial results, regulatory shifts, and innovative therapeutic approaches that are redefining patient care and drug development. Pfizer's monumental $10 billion collaboration with Innovent Biologics stands out as a testament to the shifting dynamics of the oncology sector. This partnership aims to develop 12 antibody-drug conjugate (ADC) and multispecific antibody programs, spotlighting these therapies' growing significance in oncology. The precision of antibodies in delivering cytotoxic agents directly to cancer cells offers a new frontier in minimizing collateral damage to healthy tissues—a crucial advancement in cancer treatment. The deal not only highlights Pfizer's commitment to expanding its oncology pipeline but also underscores the strategic importance of leveraging China's accelerated drug development ecosystem. In regulatory news, AstraZeneca's Imfinzi has garnered FDA approval for BCG-naive high-risk non-muscle-invasive bladder cancer. This milestone for PD-L1 inhibitors reflects the evolving landscape of immunotherapy. By harnessing monoclonal antibodies in combination therapies, the potential for enhanced anticancer efficacy is significant. With few therapeutic alternatives available, this approval presents a lifeline for many bladder cancer patients. Clinical trial outcomes also continue to capture attention. Eli Lilly's Nectin-4 targeting ADC showed promising results in advanced urothelial cancer, positioning itself as a potential competitor to Padcev. This innovation in ADC technology demonstrates the industry's relentless pursuit of targeted therapies that can revolutionize treatment paradigms. Bristol Myers Squibb's mezigdomide offers another example by showing a 52% reduction in progression risk for relapsed or refractory multiple myeloma patients, emphasizing the focus on addressing specific molecular pathways. In the realm of bispecific antibodies, Phanes Therapeutics' CLDN18.2/CD47 targeting therapy reported encouraging Phase 2 results in metastatic pancreatic ductal adenocarcinoma. These antibodies' ability to simultaneously engage multiple targets enhances their therapeutic efficacy against stubborn cancers, broadening the horizon for treatment possibilities. Meanwhile, Replimune's resubmission of its RP1 melanoma Biologics License Application (BLA) highlights the intricate dance between drug development and regulatory processes amid organizational shifts at the FDA. Such efforts reflect the continual adaptation required within the industry to navigate complex regulatory landscapes. On the funding front, Psilera's successful $8.8 million seed round indicates growing interest in psychedelic therapies for neurological conditions. Similarly, Reprogram Biosciences raised $6 million for its AI-driven cell reprogramming oncology platform, illustrating how artificial intelligence is becoming integral to advancing drug discovery and development. However, not all updates were positive. Agios Pharmaceuticals faced setbacks as their pyruvate kinase activator failed a Phase 2b trial for lower-risk myelodysplastic syndromes, serving as a sobering reminder of the inherent risks involved in drug development. Dizal Pharma emerges as a beacon of hope in lung cancer treatment following Takeda's EGFR exon 20 drug setback. By challenging existing treatments with promising small molecule data, Dizal exemplifies precision medicine's role in redefining oncology protocols—offering personalized patient options that could set new standards in treatment efficacy. The issue of drug pricing remains contentious, particularly highlighted by an AARP analysis showing an 81% increase post-launch prices stateside compared to a 13% decrease abroad. This disparity raises critical questions about achieving equitable access across markets amid Medicare negotiations and global pricing strategies like "most favored nation" policies. Regulatory updates continue with Johnson & Johnson's Tremfya label expansion stateside and AbbVie's EU extension for Venclyxto—moves that reflect efforts to maximize therapeutic reach and commercial viability across diverse geographies. Finally, Gilead Sciences' decision to discontinue its lead rheumatoid arthritis drug from MiroBio underscores ongoing challenges within emerging fields like BTLA agonists—a reminder of both innovation's promise and its perilous nature when faced with unproven therapeutic avenues. As these varied developments unfold, they collectively signal an era characterized by rapid scientific innovation and strategic collaborations across geographies alongside evolving regulatory landscapes—all driving towards enhanced patient care through more effective treatments globally. This concludes today's insights from Pharma Daily—a world where dynamic change continues reshaping healthcare delivery standards towards unprecedented possibilities for patient outcomes worldwide. Thank you for joining us; stay tuned for more updates on tomorrow's horizon-shaping advancements.Support the show

Send us Fan MailBCG interviews typically start 3–4 weeks after the application deadline – and deadlines are here. Tauseef Charanya spent 10 years at BCG – half consulting, half building AI products globally. He's done 300+ interviews and has seen strong candidates miss offers for the same reasons, over and over.In this episode, he breaks down the 3 mistakes that hurt otherwise solid BCG candidates, why doing more cases without feedback makes you worse, and the 4-step system that gets you BCG-ready.You'll learn:Why memorizing frameworks won't cut it – and what BCG interviewers are actually looking forHow BCG's candidate-led format differs from McKinsey and how to prep for itThe skill sequence that gets candidates offer-ready in 22 cases, not 100+Why the BCG internship deserves the same urgency as full-time recruitingResources:Ready to close the gap before deadlines? Book a free 15-minute consult with KatieWant the structured system Tauseef describes? Explore Black BeltBook a 1:1 session with TauseefFree Consulting Prep Just Got a Whole Lot BetterCreate a free MC account for access to step-by-step learning pathways, a brand new case prep course, and more. Download the MC app to prep anywhere.Connect With Management ConsultedCreate a free MC account or download the MC app (Apple, Android) to start your prep todaySchedule a free 15min consultation with the MC TeamWatch the video version of the podcast on YouTubeFollow us on LinkedIn, Instagram, and TikTokJoin an upcoming live event – case interviews demos, expert panels, and more

There's a single number on your routine blood test that predicts your risk of dying from cancer, heart disease, and infection better than cholesterol — and an FDA-approved drug may now move it.In this Health Longevity Secrets explainer, Robert Lufkin MD breaks down lymphopenia, the IL-15 cytokine, and ANKTIVA (nogapendekin alfa inbakicept) — the first FDA-approved IL-15 super-agonist and possibly one of the most important longevity drugs of the decade.CHAPTERS: 00:00 — Introduction: The Blood Test Number Better Than Cholesterol 00:35 — What Is Lymphopenia and Why It Matters 01:50 — Immunosenescence: Why Your T Cells Decline After Age 20 02:30 — The Mortality Data: Three Studies on Lymphopenia 03:20 — Copenhagen Study: 63% Higher All-Cause Mortality 03:50 — Coronary Angiography Study: Hazard Ratio 1.97 04:25 — Enter IL-15: The Cytokine That Builds Killer Immune Cells 05:15 — IL-15 as a Myokine: Why Resistance Training Protects Against Cancer 06:00 — Four Hallmarks of Aging Hit By One Molecule 06:30 — ANKTIVA Explained: The IL-15 Super-Agonist 07:00 — FDA Approval, Bladder Cancer, and the Soon-Shiong Reframe 08:15 — Is ANKTIVA a Longevity Drug? The Bullish Case 09:00 — The Skeptical Case: Why We Don't Know Yet 10:15 — What You Can Do Today: Track Your Number, Raise IL-15 Naturally 11:30 — Final Take and ClosingKEY TAKEAWAYS:Lymphopenia (absolute lymphocyte count below 1,500/μL) predicts all-cause mortality better than cholesterol in multiple large cohort studiesIL-15 expands NK cells and CD8+ T cells — the same cells that clear senescent "zombie" cells and patrol for cancerResistance training is the single strongest known endogenous IL-15 stimulus; your muscle signals your immune system to stay youngANKTIVA is the first FDA-approved IL-15 super-agonist (April 2024) — currently for bladder cancer but being reframed as a lymphopenia treatmentIL-15 hits four hallmarks of aging at once: immunosenescence, senescent cell accumulation, chronic inflammation, and sarcopeniaHonest take: exciting hypothesis with FDA approval, but zero human longevity trials yet — watch this spaceSTUDIES & SOURCES MENTIONED:Zidar et al., JAMA Network Open 2019 — Lymphopenia and mortality in 31,178 US adults (NHANES)Warny et al., CMAJ 2020 — Copenhagen General Population Study, lymphopenia in 108,135 adultsBawamia et al., Cardiology Journal 2022 — Lymphopenia and 8-year mortality in 15,179 coronary angiography patientsFDA approval, April 22, 2024 — Nogapendekin alfa inbakicept-pmln (ANKTIVA) for BCG-unresponsive non-muscle invasive bladder cancerWatch the full video on YouTube: https://youtu.be/220KHIdFCwg

May 26, 2026: Your daily rundown of health and wellness news, in under 5 minutes. Today's top stories: SANCTUM brings wellness raves to NYC with Othership residency, blending HIIT, yoga, and breathwork as Gen Z and millennials seek immersive high-energy wellness experiences On and Erewhon launch multi-year partnership spanning apparel, run clubs, recovery events, and co-branded post-workout juice across Erewhon locations BCG identifies 15M US "Optimizers" spending $3K annually on longevity stacks including injectables, diagnostics, GLP-1s, and supplements with medical professionals as most trusted source More from Fitt: Fitt Insider breaks down the convergence of fitness, wellness, and healthcare — and what it means for business, culture, and capital. Subscribe to our newsletter → insider.fitt.co/subscribe Work with our recruiting firm → https://talent.fitt.co/ Follow us on Instagram → https://www.instagram.com/fittinsider/ Follow us on LinkedIn → linkedin.com/company/fittinsider Reach out → insider@fitt.co

A unos 4.400 millones de años luz de la Tierra, en el corazón del cúmulo galáctico Abell 402, los científicos han descubierto la pareja de agujeros negros más masiva jamás registrada en la historia de la astronomía. Juntos, suman 60.000 millones de veces la masa de nuestro Sol, una cifra tan descomunal que destrona de golpe al que hasta ahora era el récord absoluto en masa cósmica. El misterio comenzó en 2018, cuando los telescopios detectaron algo perturbador en el centro de la galaxia Abell 402-BCG: un enorme hueco oscuro de unos 3.200 años luz de diámetro donde no brillaba absolutamente nada. La explicación inicial apuntaba a una densa nube de polvo cósmico bloqueando la luz de las estrellas, pero la ciencia tenía preparada una respuesta mucho más sorprendente. Gracias al Telescopio Espacial James Webb y al instrumento MUSE del Very Large Telescope, los astrónomos pudieron mirar a través de esa supuesta cortina de polvo. Lo que encontraron fue demoledor: el hueco no era una nube, sino un páramo estelar real, vaciado por la danza gravitacional de dos agujeros negros ultramasivos que orbitan entre sí. Una fusión inevitable que dará lugar a un único coloso de 60.000 millones de masas solares.

Dr. Lorenzo Tomé apresenta um dos pilares mais ignorados — e mais determinantes — na estruturação de um negócio médico: a gestão. Não a gestão burocrática, de planilha e POP, mas o raciocínio estratégico que separa o médico que cresce do médico que apenas sobrevive. O episódio parte de uma observação direta: o médico que mais preocupa não é o picareta — é o médico ético, excelente, que está de cabeça baixa, trabalhando mais do que deveria, sem perceber que o problema não está na medicina que ele pratica, mas na ausência de estrutura do negócio em que está. A partir daí, Lorenzo aprofunda o conceito de gestão em três dimensões — sustentabilidade, escalabilidade e relevância — e mostra como a falta de cada uma delas tem um custo real: no faturamento, no tempo, na conexão com o paciente e na realização profissional. O episódio também traz aplicações práticas: como usar a matriz BCG para mapear os serviços do consultório, por que a secretária é a gerente comercial do negócio, e como estruturar uma reunião semanal de accountability que de fato muda os números. Se você sente que entrega muito mas tem pouco espaço para crescer, esse episódio mostra onde está o travamento — e o que fazer a partir disso.   O background do Dr. Lorenzo Tomé Lorenzo Tomé é médico, fundador e CEO da SD Escola de Negócios Médicos — escola especializada em estruturação de modelos de negócio para médicos com ética, método e previsibilidade. Com mais de 500 médicos capacitados, desenvolveu uma metodologia própria baseada em receita recorrente por acompanhamento longitudinal, que combina gestão, marketing, vendas, finanças e tecnologia aplicados à prática clínica. Atua como mentor direto de médicos em diferentes especialidades, ajudando-os a construir negócios sustentáveis, escaláveis e alinhados com o propósito de cuidar. Entre na Comunidade SD no WhatsApp e tenha conteúdo gratuito todos os dias sobre negócios médicos. Assista esse episódio também em vídeo no Youtube no nosso canal Saúde Digital Podcast! Acesse os episódios anteriores! SD359 - Da consulta avulsa ao acompanhamento longitudinal: o papel da Medicina de Estilo de Vida na sua receita SD358 - Upsell ético no consultório: mercado de wellness sem "empurroterapia" SD357 - As consultas avulsas estão falindo Musica: Declan DP - Echo Music © Copyright Declan DP 2018 - Present. https://license.declandp.info | License ID: DDP1590665  

Kristy Ellmer has spent her career leading large-scale transformations across industries, countries, and operating environments. In this conversation, she explains why most change efforts fail — not because of bad strategy, but because organizations underestimate the human side of execution. A central idea from the discussion is the imbalance between the "what" and the "how" of transformation. Leaders spend enormous energy defining strategy, targets, and operating levers, but far less time on the behaviors and systems required for adoption. As Ellmer explains, "transformations or change are failing… on the elements of the how. It's not because there was bad strategy." She argues that many executives rush from alignment into execution before the organization is ready. One of the most counterintuitive lessons from her work is the need to pause after agreement is reached: "You need to take… up to two months to get organized." Without the right operating structure, early momentum eventually stalls. The conversation also explores why momentum must be designed intentionally. Discussing transformation work at Aetna, Ellmer explains the importance of visible early wins and helping employees understand "what's in it for you." She emphasizes that leaders are "responsible for momentum," not just strategy. Another major theme is resistance to change. Early in her career, Ellmer believed that "everybody will just get on board because things are right." Experience taught her otherwise. Different groups respond to different incentives, fears, and motivations. Her advice: "Be curious" about why people resist rather than assuming they are unwilling to change. She also challenges traditional views of change management, arguing that communication plans and training sessions alone are insufficient. "There is real science now out there on how humans really change," she says, and organizations that ignore that science struggle to achieve lasting adoption. The discussion also covers: why long transformations create fatigue when organizations never create "endings" how senior leaders should think about AI adoption versus AI hype why most companies are integrating AI as a workflow tool rather than fully replacing human work what separates successful consulting partners from those who simply "tick boxes" why career growth often comes from "leaning into uncertainty" Throughout the episode, Ellmer returns to one principle: organizations execute change more effectively when they treat employees with the same intentionality they would apply to external customers. "It's your job to sell the change," she says — not simply announce it. Kristy Ellmer is a Managing Director and Senior Partner at BCG and a former Chief Transformation Officer, with decades of experience leading multiyear transformations inside global organizations. She is a coauthor of the book, How Change Really Works. Get Kristy's book, How Change Really Works, here: https://tinyurl.com/2zb4p63d Claim your free gift: Free gift #1 McKinsey & BCG winning resume www.FIRMSconsulting.com/resumePDF Free gift #2 Breakthrough Decisions Guide with 25 AI Prompts www.FIRMSconsulting.com/decisions Free gift #3 Five Reasons Why People Ignore Somebody www.FIRMSconsulting.com/owntheroom Free gift #4 Access episode 1 from Build a Consulting Firm, Level 1 www.FIRMSconsulting.com/build Free gift #5 The Overall Approach used in well-managed strategy studies www.FIRMSconsulting.com/OverallApproach Free gift #6 Get a copy of Nine Leaders in Action, a book we co-authored with some of our clients: www.FIRMSconsulting.com/gift  

In this episode, UROONCO BCa chief editor Dr. Benjamin Pradere interviews Dr. Trinity Bivalacqua on the first results from CORE-008 Cohort CX- phase 2 study of intravesical cretostimogene grenadenorepvec with gemcitabine in patients with high-risk BCG-exposed or BCG-unresponsive non-muscle invasive bladder cancer. They talk in detail of the rational and results of this cohort, and the role of cretostimogene in treatments of BCG-exposed or BCG-unresponsive bladder cancer. For more details on this study, you can read the abstract on the UROONCO BCa Educational Platform.This interview was recorded at AUA2026. For more updates on bladder cancer, please visit our educational platform UROONCO BCa.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

In this episode of Future Finance, Paul Barnhurst and Glenn Hopper speak with Ali Hussain, CEO and co-founder of Tabs, an AI-powered platform revolutionizing finance workflows. Ali discusses the limitations of legacy finance systems, the challenges of modern revenue models, and how AI is automating the full contract-to-cash cycle for finance teams.Ali Hussain is the CEO and co-founder of Tabs, where he leads the development of AI-native solutions designed to automate the billing, collections, and revenue recognition process. With a background spanning product leadership at Google, strategy consulting at BCG, and public policy, Ali is at the forefront of the next wave of finance technology.In this episode, you will discover:How automation is transforming the finance sector, particularly revenue managementThe importance of structured data for effective financial solutionsWhy traditional finance systems struggle with modern revenue modelsHow Tabs is automating billing, collections, and revenue recognitionThis episode provides insights into how automation is reshaping finance, helping businesses manage revenue models and streamline financial tasks. Ali Hussain shares his perspective on simplifying finance workflows and the direction the industry is heading. Follow Ali:Website: https://www.tabs.comLinkedin: https://www.linkedin.com/in/ali-hussain786/ YouTube: https://www.youtube.com/@tabsplatform Follow Glenn:LinkedIn: https://www.linkedin.com/in/gbhopperiiiFollow Paul:LinkedIn - https://www.linkedin.com/in/thefpandaguyFollow QFlow.AI:Website - https://bit.ly/4i1EkjgFuture Finance is sponsored by QFlow.ai, the strategic finance platform solving the toughest part of planning and analysis: B2B revenue. Align sales, marketing, and finance, speed up decision-making, and lock in accountability with QFlow.ai. Stay tuned for a deeper understanding of how AI is shaping the future of finance and what it means for businesses and individuals alike.In Today's Episode:[02:00] – Ali's Background and Tabs' Growth[03:00] – Automation in Finance[05:00] – Agents in Finance Workflows[08:00] – Data Quality in Finance[10:00] – Limitations of LLMs in Finance[12:00] – Agents vs Automation[15:00] – The Future of Finance[17:00] – Managing Usage-Based Pricing[21:00] – Closing Thoughts

Send us Fan MailBCG quietly updated its Consulting Career Assessment (CCA) and most candidates approach it the wrong way.In this episode, Katie – ex-BCG, Black Belt Advisor at Management Consulted – breaks down the revamped CCA across each section, so you know what to expect.What most candidates miss: this isn't just a math test. BCG is measuring who you are and whether you are consistent in your answers.You'll learn:Why consistency matters more than picking the "right" answerThe elimination strategy that helps you move faster on problem-solving questionsWhat appearing neutral or inconsistent signals to BCG — and why it's a red flagResources:Join Black Belt – includes 4 CCA practice versions + full interview prep coachingBook 15 minutes with Katie – talk through your support options and whether Black Belt is right for youConnect With Management ConsultedCreate a free MC account or download the MC app (Apple, Android) to start your prep todaySchedule a free 15min consultation with the MC TeamWatch the video version of the podcast on YouTubeFollow us on LinkedIn, Instagram, and TikTokJoin an upcoming live event – case interviews demos, expert panels, and more

Women raise just 2% of venture capital. Naseem is on a mission to move that number and she has some uncomfortable truths about why women keep losing the room before they've even pitched. Naseem spent years at BCG Digital Ventures as one of just two female partners out of forty-five worldwide, sitting in boardrooms where capital flowed freely everywhere except towards women. She left to co-found Emmeline Ventures, a seed-stage fund backing female founders in health tech, financial services, and sustainability, and now works with female founders to fundraise and scale innovation. We explore: - Why women still get called "abrasive" while men get called "proactive", and the BCG experiment that proved the bias was real - The pitching reframe that rewires your brain so you can tell the story investors need to hear: "Lead with money. Put the empathy in the appendix." - Why picking up the coffee cups, taking the notes, and finishing sentences with an upward inflection is costing women deals, and promotions - The IVF journey that reshaped Naseem's career, purpose, and view on health tech for women (female founders in healthcare knew more about her body than her doctor did) - How to build investor relationships to fundraise successfully (how men raise $10M over a weekend, and why you aren't) - Why "abundance" is a strategy, not a vibe  Chapters 00:00  The 2% problem: why women still aren't getting the capital 02:00  Inside BCG: politics, lobbying for promotions, and life as the lone female partner 05:00  The newborn moment that ended her consulting career 07:30  Job descriptions, performance reviews, and the experiments that actually moved the needle 10:30  Confidence, the cups, and the notebook trap 14:00  Why women don't talk about money — and the deconditioning we owe ourselves 16:30  "Lead with money. Put the empathy in the appendix." 22:00  IVF, female health, and the capital disparity she couldn't unsee 27:00  Building Emmeline Ventures and changing where capital flows 31:00  Building investor trust before you need it. Living in abundance. Connect with Naseem: Her Linkedin Her Podcast "The Capital Flex Podcast" Connect with me:IG: https://www.instagram.com/whereboundariesdissolvepodcast/TikTok: https://www.tiktok.com/@helena.arjuna?_t=8oSbtTilPSQ&_r=1LinkedIn: https://www.linkedin.com/in/helenasuter/ Support the show

With the half-life of professional skills shrinking every year, is the traditional model of corporate learning and development fundamentally broken, and what role should employers play in the new era of continuous education?Agility requires a workforce that can adapt and acquire new skills as quickly as the market changes. This means the old models of education and professional development must be re-engineered for a world that demands continuous learning integrated with professional life.Today, we're going to talk about the evolution of higher education, specifically how online programs are being redesigned from the ground up to meet the complex needs of working adults. We'll explore how concepts we often discuss in customer experience—like personalization and flexibility—are being applied to learning to help professionals advance their careers without putting the rest of their lives on hold.To help me discuss this topic, I'd like to welcome, Ruth Veloria, Chief Strategy and Customer Officer at University of Phoenix. About Ruth Veloria Ruth Veloria is Chief Strategy and Customer Officer at the University of Phoenix, where she leads strategic vision, customer experience innovation, and the use of student data to support progress, graduation, and career success. She joined the University in 2009 and has held roles including chief customer officer and executive dean of the Business School, with prior strategy experience at Booz Allen, BCG, and Charles Schwab. Veloria holds a bachelor's degree in chemistry from New College at the University of Oxford and a master's in management from the Kellogg School at Northwestern University. Ruth Veloria on LinkedIn: https://www.linkedin.com/in/ruthveloria/ Resources University of Phoenix: https://www.phoenix.edu/ The Agile Brand podcast is brought to you by TEKsystems. Learn more here: https://aglbrnd.co/r/2868abd8085a9703 Drive your customers to new horizons at the premier retail event of the year for Retail and Brand marketers. Learn more at CRMC 2026, June 1-3. https://aglbrnd.co/r/d15ec37a537c0d74 We're proud to be a media partner for #MAICON26 - Oct. 13-15! Learn how AI can power your marketing and business and help you grow smarter. Use code AGILE150 to save! https://aglbrnd.co/r/7fe458ced0f04658Reach your customers with Reddit. Spend $500 in ad spend, get $500 back in ad credit! Learn more: https://advertalize.com/r/491818c79fb1873f Enjoyed the show? Tell us more at and give us a rating so others can find the show at: https://aglbrnd.co/r/faaed112fc9887f3 Connect with Greg on LinkedIn: https://www.linkedin.com/in/gregkihlstromDon't miss a thing: get the latest episodes, sign up for our newsletter and more: https://aglbrnd.co/r/35ded3ccfb6716ba Check out The Agile Brand Guide website with articles, insights, and Martechipedia, the wiki for marketing technology: https://www.agilebrandguide.com The Agile Brand is produced by Missing Link—a Latina-owned strategy-driven, creatively fueled production co-op. From ideation to creation, they craft human connections through intelligent, engaging and informative content. https://www.missinglink.company Hosted on Acast. See acast.com/privacy for more information.

MoneyWise is a Hampton podcast. Hampton is a private, vetted community for founders doing $3M or more in revenue. Apply at https://www.joinhampton.com/?utm_source=youtube&utm_medium=video&utm_campaign=yt051126.From Minecraft maps to $400k months — but the money isn't the story.Nathan May grew up in one of the poorest neighborhoods in Ohio. His mom made $32,000 a year. He never left the state until he was 18. At 15, he was selling custom Minecraft maps to famous YouTubers and making his first $100K. He went to Wharton, joined BCG, quit, and built one of the fastest-growing newsletter agencies in the country before turning 30.But the week he hit his first million dollars, his mom died. And he felt nothing.In this episode, Nathan gets brutally honest about what money actually gave him — and what it didn't. We go deep on the community he's built in New York with a group of founders sharing an office, a monthly revenue leaderboard, and the kind of real talk that doesn't happen anywhere else. He calls it the Media Mafia. He says it's changed his life more than any dollar amount ever has.We also get into:Growing up in poverty and never leaving Ohio until 18How a Minecraft addiction became his first real businessLeaving a six-figure BCG career to bet on himselfBuilding a $1M ARR agency in under a year with 1,000 newsletter subscribersHis actual net worth, his $10M target, and why he keeps almost no cashWhy he thinks the wealthiest people he knows are often the least happyTimestamps00:00 - Cold open00:58 - Introducing Nathan May01:23 - Small talk / how Nathan starts his day02:32 - The agency, the numbers, how life has changed03:24 - Growing up poor in Ohio — never left the state until 1805:35 - He originally wanted to be an actor06:04 - The Minecraft business: how a video game addiction made him $100K at 1509:05 - Wharton, Wall Street culture shock, and the path to BCG10:36 - What BCG actually changed about his life12:01 - Building the agency: newsletters, Schwarzenegger, and why it felt like video games again15:32 - His real relationship with money: checking account, savings, leverage strategy16:52 - The $10M number: how he used ChatGPT to find his "enough"18:34 - The Media Mafia: seven founders, one office, a monthly revenue leaderboard20:31 - Being at the cusp — exciting, terrifying, or both?23:07 - Why IRL community is the highest-leverage thing a founder can build26:03 - What Hampton means to him27:31 - His mom's passing, the $1M milestone, and why none of it felt like anything29:24 - Can you be successful without community?31:39 - What's next and closing thoughtsMoneyWise is the podcast where high-net-worth founders get radically transparent about how they actually make, spend, invest, and think about money. Hosted by Daniel Berk and presented by Hampton.Sponsors:Daily Body Coach - achieve your dream body with https://moneywise.dailybodycoach.com

Send us Fan MailSebastian is a Purdue junior with Bain interviews coming up. He ran a full first-round Bain case live – and after every section, coach Mitali stopped and told him exactly what worked and what he missed.Mitali spent 5 years in consulting, including as a senior consultant at Bain in London. She's coached 350+ people into MBB and used to interview candidates herself – so she knows what Bain is looking for.You'll see:Why "financial vs. non-financial" is too generic for Bain – and what to say insteadHow to read an exhibit the way Bain wants it doneThe math mistake Sebastian made live – and how he recoveredHow to give a final recommendation backed by the numbers, not your gutCoaching with Mitali:Join the Black Belt case prep program for personalized coaching with Mitali and a prep strategy tailored to your goals and timelineConnect with Mitali on LinkedInResources:Create a free account to access Case Interview Foundations – a 7-day case interview crash courseWatch more McKinsey, BCG, and Bain case interview demos on YouTubeFree Consulting Prep Just Got a Whole Lot BetterCreate a free MC account for access to step-by-step learning pathways, a brand new case prep course, and more. Download the MC app to prep anywhere.Connect With Management ConsultedCreate a free MC account or download the MC app (Apple, Android) to start your prep todaySchedule a free 15min consultation with the MC TeamWatch the video version of the podcast on YouTubeFollow us on LinkedIn, Instagram, and TikTokJoin an upcoming live event – case interviews demos, expert panels, and more

Akbank katkılarıyla hazırladığımız 304. bölümde; McKinsey, Deloitte, Gartner, BCG ve Wavestone'un 2026 raporlarından yola çıkarak şirketlerin yapay zekâ dönüşümünde neden zorlandığını konuşuyoruz. Pilot dönem gerçekten bitti mi, şirketler neden ölçekleme sorunu yaşıyor, teknoloji yatırımı kadar insan yatırımı neden kritik hale geliyor ve önümüzdeki yıllarda şirketler arasındaki fark neden daha da açılacak gibi sorulara birlikte bakıyoruz. Sen de Akbank Mobil'den Nakit Akışınla Kazan programına katıl, toplamda 30.000 TL'ye varan chip-para ve 1 yıl ücretsiz EFT/havale kazan. Detaylar: https://www.akbank.com/kampanyalar/akbank-mobil-nakit-akisinla-kazan-kampanyasi Bu bölüm Akbank hakkında tanıtım içerir (00:00) Açılış(00:23) Bölüm açılışı ve raporların ortak mesajı: “Pilot dönem bitti”(00:48) Deloitte raporundaki CEO sözü ve teknolojinin eskime hızı(01:15) “Gerçekten pilot dönem bitti mi?” sorusu(01:42) McKinsey verileri: Şirketlerin %88'i AI kullanıyor(02:05) Şirketlerin %86'sı AI entegrasyonuna hazır olmadığını düşünüyor(02:30) BCG raporu: Ölçeklendirme var ama ölçülebilir fayda sınırlı(03:00) Deloitte verileri: AI ajanlarında üretime geçen şirket oranı(03:22) Genel tablo: Herkes deniyor ama çoğu ölçekleyemiyor(03:40) KOBİ'lerin dönüşüm ve nakit yönetimi baskısı(03:55) Akbank Nakit Akışında Kazan programı(04:03) “Neden bu kadar çok şirket sıkışıyor?” sorusu(04:20) Gartner tahmini: Agentik AI projelerinin %40'ı başarısız olacak(04:45) Bozuk süreçleri optimize etmenin riski(05:05) CFO örneği: Uçtan uca süreç dönüşümü yaklaşımı(05:32) Wavestone raporu ve siber güvenlik perspektifi(05:55) Tehditlerin merkeze değil çevreye kayması(06:10) Yapay zekâda asıl dönüşümün müşteri temas noktalarında yaşanması(06:28) McKinsey: Teknolojiye 1 dolar, insana 5 dolar harcanmalı(06:58) Şirketlerin 3 gruba ayrılması(07:10) 1. grup: Gerçekten dönüşen şirketler(07:28) Walmart örneği ve çalışanlarla uygulama geliştirme(07:52) 2. grup: “Pilot cehennemi” içinde kalan şirketler(08:18) McKinsey verisi: AI'ın net sahibi olmayan şirketler(08:30) 3. grup: Henüz başlamayan ama hazırlanan şirketler(08:53) Önümüzdeki yıllarda şirketler arasındaki farkın açılması(09:05) Coca-Cola CEO'sunun yaklaşımı: “Ne yapabiliriz?” yerine “Ne yapmalıyız?”(09:38) Uzun vadeli performans ve stratejik netlik vurgusu(10:00) Her şeyi yapmaya çalışan şirketlerin kaybetme riski(10:12) Bölüm özeti ve raporların ortak hissi: Aciliyet(10:40) Beklemenin maliyeti ve “bir şeyler yapıyoruz” rahatlığının bitmesi(10:58) Kapanış sorusu: AI'a karşı insana yapılan yatırım oranı(10:28) Kapanış ve veda McKinsey — The State of AI 2025 https://www.mckinsey.com/capabilities/quantumblack/our-insights/the-state-of-ai McKinsey — The State of Organizations 2026 https://www.mckinsey.com/~/media/mckinsey/business%20functions/people%20and%20organizational%20performance/our%20insights/the%20state%20of%20organizations/2026/the-state-of-organizations-2026.pdf Deloitte — Tech Trends 2026 https://www.deloitte.com/us/en/insights/topics/technology-management/tech-trends.html (PDF doğrudan: https://mkto.deloitte.com/rs/712-CNF-326/images/DI_Tech-trends-2026.pdf) Gartner — Agentic AI Projects Press Release https://www.gartner.com/en/newsroom/press-releases/2025-06-25-gartner-predicts-over-40-percent-of-agentic-ai-projects-will-be-canceled-by-end-of-2027 BCG — The Widening AI Value Gap: Build for the Future 2025 https://media-publications.bcg.com/The-Widening-AI-Value-Gap-Sept-2025.pdf (Ana sayfa: https://www.bcg.com/publications/2025/are-you-generating-value-from-ai-the-widening-gap) Wavestone — Technology Trends 2026 https://www.wavestone.com/en/insight/technology-trends-2026/ Sosyal Medya takibi yaptın mı? ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠X⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  – ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ – ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Linkedin⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ – ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Youtube⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ – ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Goodreads⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Bülten⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ – ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠E-Posta⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ – Bu çalışmaları ve emeklerimi desteklemek için ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Patreon⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  ve ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Buy Me A Coffee⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ hesabımız⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

Sales teams are no longer defined by a few superstar performers. Japjit Ghai, who leads BCG's AI efforts for sales globally, explains how AI is reshaping the entire sales workflow—from lead prioritization to real-time coaching and closing the deal. Winners won't bolt on tools. They'll integrate AI and agents from end to end.Learn More:Japjit Ghai: https://on.bcg.com/48IzJiVHow AI Agents Will Transform B2B Sales: https://on.bcg.com/4dnWPOrHow AI Can Reshape Distributed Sales Channels in Emerging Markets: https://on.bcg.com/4tSL0puBCG's Latest Thinking on Marketing and Sales: https://on.bcg.com/4utKWMJImagine This... on the future of sales: https://lnk.to/imagine-this-Andersen-sales09Chapters(0:00) The End of Superstar Salespeople?(1:26) Is AI Moving Into the Sales Frontline?(1:57) Is This Shift Across the Board?(3:01) What Happens to Top Sales Performers?(4:08) Where AI Still Falls Short in Sales(4:47) Why Talent Is Choosing AI-First Companies(5:06) What Augmented Selling Looks Like(6:07) Real-Time AI Sales Assistant Demo(10:13) The ROI of AI in Sales(11:00) What Sellers Gain (and Fear Losing)(11:40) How Performance Is Measured(12:26) Misconceptions Leaders Have About Using AI In Sales(13:14) Will Customer Relationships Suffer?(14:59) When You Should NOT Use AI(16:22) What Great AI Sales Looks Like(17:18) Is There an AI Blueprint to Follow for Sales?(17:58) What Will the Future Look Like in AI Sales?(18:39) Next Steps for LeadersThis podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

In this episode of Future Finance, Paul Barnhurst and Glenn Hopper speak with Ali Hussain, CEO and co-founder of Tabs, an AI-powered platform revolutionizing the revenue process for finance teams. Ali discusses how the traditional ERP systems have left revenue management behind, and how Tabs is changing the game by automating the full contract-to-cash cycle. He shares his insights on the complexity of revenue management, AI's role in financial systems, and why understanding the data context is key to success in AI-powered finance tools.Ali Hussain is the CEO and co-founder of Tabs, where he leads the development of AI-native solutions designed to automate the billing, collections, and revenue recognition process. With a background spanning product leadership at Google, strategy consulting at BCG, and public policy, Ali is at the forefront of the next wave of finance technology.In this episode, you will discover:How AI is transforming revenue management in financeThe importance of data context in AI-powered toolsWhy traditional finance systems fail to address modern revenue modelsHow Tabs automates billing, collections, and revenue recognitionAli Hussain shared invaluable insights into the future of finance, highlighting how AI is revolutionizing revenue management and financial operations. While AI brings immense potential for automation, human judgment remains crucial in making strategic decisions. Follow Ali:Website: https://www.tabs.comLinkedin: https://www.linkedin.com/in/ali-hussain786/ YouTube: https://www.youtube.com/@tabsplatform Follow Glenn:LinkedIn: https://www.linkedin.com/in/gbhopperiiiFollow Paul:LinkedIn - https://www.linkedin.com/in/thefpandaguyFollow QFlow.AI:Website - https://bit.ly/4i1EkjgFuture Finance is sponsored by QFlow.ai, the strategic finance platform solving the toughest part of planning and analysis: B2B revenue. Align sales, marketing, and finance, speed up decision-making, and lock in accountability with QFlow.ai. Stay tuned for a deeper understanding of how AI is shaping the future of finance and what it means for businesses and individuals alike.In Today's Episode:[00:00] – Trailer[03:00] – Legacy Finance Systems[06:15] – Revenue Management Gaps[09:00] – How Tabs Transforms Finance[12:00] – AI in Billing & Rev Rec[15:30] – Clean Data Importance[19:00] – AI vs Human Judgment[22:30] – The Future of AI[25:00] – Complex Revenue Models[29:00] – AI Challenges in Finance[34:00] – Closing Thoughts on AI

"We thought, from a nursing standpoint, 'What is our goal for doing this?' What we wanted was first, education of the patient. Can we successfully educate the patient to prepare them? Can we alleviate as much anxiety as possible so that they feel comfortable coming in and having this done? The second goal is to preserve kidney function throughout the treatment. To date, we've been successful with that. And the third goal is to complete treatment without infection," ONS member Chris Amoroso, BSN, RN, OCN®, registered nurse at Fox Chase Cancer Center in Philadelphia, PA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about intrarenal administration for upper urothelial tract disease. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by May 1, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Nurses caring for people with cancer require knowledge of the different routes for drug administration, including intrarenal administration via a percutaneous nephrostomy. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Episode 141: Care Coordination for Urothelial Cancer Episode 133: Treatment Advancements for Advanced or Metastatic Urothelial Cancer ONS Voice articles: A Primer on Urothelial Cancer Chemo Combo May Be a Bladder Cancer Treatment Alternative During BCG Shortage Nurses Are Key to Patients Navigating Genitourinary Cancers Clinical Journal of Oncology Nursing articles: Avelumab First-Line Maintenance Therapy: Managing Patients With Advanced Urothelial Carcinoma Percutaneous Nephrostomy Infusion: Nursing Considerations for Treatment of Upper Urinary Tract Urothelial Carcinoma ONS Learning Libraries: Cancer of the Genitourinary Tract Safe Handling of Hazardous Drugs To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "In an office setting, it's not something we can really visualize. Patients will present with hematuria or flank pain, obstructions in the ureter, some hydronephrosis, they may be having a lot of urinary tract infections. And a routine cystoscopy in the office is not going to visualize the ureters. We can do biopsies like a ureteroscopy, a computerized tomography urogram, or a urine cytology. And those are usually the main ways of diagnosing upper tract disease—again, because it's rare." TS 2:33 "We ask patients to get into a comfortable position where they can sit or lay for an hour without too much movement. The movement of their body position can interfere with the flow of the medication going in. ... When we're ready to start, we're cleaning the ends of the nephrostomy tube and the IV tubing with a chlorhexidine solution. We're instilling this using micro drip tubing. The tubing has to be microchipped so we can accurately control the flow. The IV bag with medication is hung about 10 inches above kidney level. And the reason we do that is because we do not want to increase the intrarenal pressure. ... We want a slow infusion via gravity over about an hour. We're watching throughout the procedure to make sure that there's no leakage, no discomfort, really just watching the patient and having that communication with the patient. Are they feeling anything different? Do we notice a difference in the flow rate? Is it slowing down? And if so, why is it? Did the patient change position? If we have any [instance] where the patient says, 'I can feel something there,' or we see leakage, we stop that infusion immediately, emphasizing that it has to be gravity, never on a pump." TS 7:30 "We go over all the bacillus Calmette-Guérin (BCG) precautions because this is the drug that we're giving. As if we were doing traditional intravesical therapy such as placing a catheter up into the bladder, we're still giving patients BCG. So, we need them to follow the special precautions. We ask every patient, regardless of the drug we're giving them, to sit down to urinate, pour two cups of bleach in the toilet, let it sit for about 15 minutes, then close the lid and flush twice. Even though we're giving this for upper tract disease, it's still being excreted into the urine. So, precautions need to be followed. Sitting down to urinate to avoid splashing of the drug, putting the two cups of bleach in every time they urinate for a duration of six hours, closing the lid, and then flushing that toilet twice. The same precautions, whether it's traditional intravesical or intrarenal." TS 14:20 "The induction phase is the first six installations. So, the first time we give this drug, we're doing it once a week for six weeks. And during those six weeks, we're communicating with the patient. We'll do a follow-up phone call and ask, 'How are you feeling? Any issues?' And we do get to know our patients really well. ... If they call, we're going to send them for a urine culture and make sure there's nothing there. ... After those six weeks, we make sure the patient understands that this is not one course and done. We want to continue to do this to give them the best chance at preventing recurrence. After we've done those six, we'll wait about four to six weeks, and then we'll do a cystoscopy and ureteroscopy in the operating room to make sure we have the response we're looking for. Again, letting the patients know because sometimes they don't understand that this is going to continue—it's not six treatments and done." TS 23:08 "You can't think of this as the same as bladder cancer. This is in the upper tract. We can't approach it as if it was non-muscular invasive bladder cancer. The diagnosis is different. It's harder to diagnose. Again, we're not visualizing the ureters in a routine office cystoscopy.  ... You can't resect it out. When I was talking to our surgeon, he said, 'You can't resect the urothelial disease in the ureters like you would in a bladder tumor.' You can't go and just pick it apart. It's a little bit more complex than that. You can't go in and resect out lesions in the ureter itself." TS 36:20

Send us Fan MailOnly 19% of McKinsey's new hires today are MBAs. In the mid-90s, that number was over 80%.The # of spots available for MBAs is shrinking – the competition isn't.MC coach Catherine Lee – ex-Deloitte, ex-BCG, Harvard MBA – breaks down 3 mistakes that sink most incoming MBAs before they ever reach an interview:Starting too late (fall semester is already too late)Treating prep like a sprint instead of a marathonPracticing cases without a system to track your gapsPlus: the summer prep roadmap that gets you ahead of your entire cohort before school starts.Katie Neff (Black Belt Advisor) joins with data from 250+ BB members who landed at McKinsey, Bain, and BCG – including the 22-case benchmark.Resources:Want structured support before the semester starts? Join Black BeltNot sure yet? Book 15 minutes with KatiePre-MBA program deadlines start May 3Free Consulting Prep Just Got a Whole Lot BetterCreate a free MC account for access to step-by-step learning pathways, a brand new case prep course, and more. Download the MC app to prep anywhere.Connect With Management ConsultedCreate a free MC account or download the MC app (Apple, Android) to start your prep todaySchedule a free 15min consultation with the MC TeamWatch the video version of the podcast on YouTubeFollow us on LinkedIn, Instagram, and TikTokJoin an upcoming live event – case interviews demos, expert panels, and more

Two Onc Docs, hosted by Samantha A. Armstrong, MD, and Karine Tawagi, MD, is a podcast dedicated to providing current and future oncologists and hematologists with the knowledge they need to ace their boards and deliver quality patient care. Dr Armstrong is a hematologist/oncologist and assistant professor of clinical medicine at Indiana University Health in Indianapolis. Dr Tawagi is a hematologist/oncologist and assistant professor of clinical medicine at the University of Illinois in Chicago.In this episode, OncLive On Air® partnered with Two Onc Docs to provide a comprehensive review of localized bladder cancer, covering everything from initial histology to the rapidly evolving treatment paradigms for muscle-invasive disease. Drs Armstrong and Tawagi emphasized that although urothelial carcinoma remains the most common bladder cancer histology, recognizing variants like squamous, adenocarcinoma, and small cell is vital, as they often require surgery-first approaches or specialized chemotherapy. A critical diagnostic pearl highlighted for oncology boards was the necessity of muscularis propria in the transurethral resection of the bladder tumor (TURBT) specimen. If muscle is absent, a repeat TURBT is mandatory to ensure the cancer is not under-staged. For non–muscle-invasive bladder cancer, the treatment goal is preventing recurrence and progression. Patients with high-risk disease should receive BCG induction and maintenance. For those who are BCG unresponsive, Drs Armstrong and Tawagi discussed several novel intravesical therapy options that may be preferred over systemic pembrolizumab to avoid toxicity.The management of muscle-invasive bladder cancer (MIBC) is primarily dictated by cisplatin eligibility, which is determined by performance status, renal function, and the absence of neuropathy or hearing loss. In cisplatin-eligible patients, the phase 3 NIAGARA trial (NCT03732677) results led to a new standard of care (SOC), which is the addition of durvalumab (Imfinzi) to a gemcitabine/cisplatin backbone. Furthermore, the phase 3 KEYNOTE-B15 trial (NCT04700124) data demonstrated that neoadjuvant enfortumab vedotin-ejfv (Padcev) plus pembrolizumab (Keytruda) significantly improved overall survival compared with standard chemotherapy, though this combination is not yet the board-tested standard. For cisplatin-ineligible patients, the phase 3 EV-303 trial (NCT03924895) established neoadjuvant enfortumab vedotin plus pembrolizumab as a new SOC, replacing the previous approach of upfront cystectomy followed by adjuvant nivolumab (Opdivo).Finally, Drs Armstrong and Tawagi discussed trimodal therapy as a bladder-sparing treatment approach. Ideal candidates for this approach must have small tumors, a complete TURBT, no hydronephrosis, and must commit to lifelong cystoscopic surveillance.

"They are small, powerful little nuggets. They are actually small signaling proteins that our immune cells use to communicate. They really help regulate immune activation or inflammation and even the growth and survival of immune cells. When cytokines are used therapeutically in oncology, they help to stimulate immune cells such as T cells or natural killer cells to better recognize and attack cancer cells," Maribel Pereiras, PharmD, BCPS, BCOP, clinical pharmacy specialist at the John Theurer Cancer Center of Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about the cytokine drug class. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours (including 30 minutes of pharmacotherapeutic content) of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by April 24, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Nurses caring for people with cancer require knowledge of cytokines to provide appropriate education and to safely administer related therapies. Episode Notes  Complete this evaluation for free NCPD.  ONS Podcast™ episodes: Pharmacology 101 series Episode 256: Cancer Symptom Management Basics: Hematologic Complications Episode 196: Oncologic Emergencies 101: Bleeding and Thrombosis ONS Voice articles: FDA Approves Nogapendekin Alfa Inbakicept-Pmln for BCG-Unresponsive Non–Muscle Invasive Bladder Cancer Manage Cancer-Associated Anemia With Erythropoietin-Stimulating Agents Oncology Drug Reference Sheet: Motixafortide ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) and 2024 Drug Supplement Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) Guide to Cancer Immunotherapy (second edition) Clinical Journal of Oncology Nursing article: Tumor-Infiltrating Lymphocyte Therapy for Melanoma: Nursing Considerations What's Old Is New Again, Unfortunately ONS Symptom Interventions Colony-Stimulating Factors Including Biosimilars for At-Risk Patients for Prevention of Infection: General Platelet Growth Factors for Prevention of Bleeding National Comprehensive Cancer Network To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Cytokines are actually among some of the earliest forms of immunotherapy used in the treatment of cancer, and it really goes back to the 1980s and the 1990s. We're talking therapies like interferon [alpha] or interleukin-2 that were used to stimulate the immune system, with the idea that they would recognize and attack cancer cells, particularly in diseases like metastatic melanoma and renal cell carcinoma. What made these therapies unique was that although the overall response rates were relatively modest, when patients did respond, those responses could be very durable and sometimes long lasting. And that observation was really important for the field of oncology, because it was part of the process that demonstrated that the immune system could potentially control cancer in really meaningful ways." TS 1:49 "One nice new example of an engineered cytokine is nogapendekin alfa inbakicept, which is quite the tongue twister to say. … This agent is really interesting because it's an engineered interleukin-15 receptor agonist that works on stimulating natural killer cells and CD8-positive T cells. And what makes this so interesting is that it's used in combination with a medication that probably some of us are familiar with—good old BCG—for patients specifically with invasive bladder cancer. The other really interesting thing about this new therapy is the fact that it is one of our first ones to be engineered in a combination fashion. So the nogapendekin alfa is combined with a receptor component that is called inbakicept. And what happens is it forms a complex to enhance signaling and prolong the activity of the cytokine." TS 7:50 "When you're looking at our therapeutic cytokines, those tend to produce larger-scale systemic inflammatory effects leading to much more global side effect reactions, while your supportive care cytokines are more commonly associated with either bone marrow stimulation effects or hematologic changes." TS 14:01 "Regardless of what type of cytokine therapy may you be using, across the board, early recognition of the symptoms and proactive supportive care are really important. And this is where many of our oncology nurses play such a critical role in identifying changes that are happening in real time to the patient's condition and helping to coordinate, relay information to the rest of the providing team so that timely interventions can occur for the best care of the patient." TS 18:01 "The other fascinating thing about these cytokines is that they're not being used as monotherapy anymore. They're now being looked at in combination with other therapies or even other immunotherapies like our checkpoint inhibitors. They're being looked at in the sense that they may be able to help expand and further activate immune cells that our current therapies rely on. And so it's really interesting that while cytokines were some of the earliest forms of cancer immunotherapy, they're now being reimagined as part of modern combination strategies designed to really further help enhance the immune responses against cancer." TS 29:08

More than 70% of CEOs are under chronic stress—but the real sources might surprise you.Drawing on BCG's CEO Insomnia Index, Judith Wallenstein and Christine Barton unpack what's driving the pressure, why it's coming from closer than expected, and how it's starting to impact decision-making at the top. While performance, growth, and cost pressures remain constant, the real weight is coming from much closer to home: boards, leadership teams, and employees.You'll learn:The surprising stakeholders creating the most pressureHow stress narrows creativity, judgment, and strategic thinkingWhy the CEO role is becoming more isolatingWhat leaders can do to manage energy, time, and expectations more effectivelyLearn More:Christine Barton: https://on.bcg.com/4twIHs8Judith Wallenstein: https://on.bcg.com/4vCcMrrThe BCG CEO Insomnia Index: https://on.bcg.com/492jygqWhat Boards Expect of CEO Candidates: https://on.bcg.com/48hfzwdThe CEO's Guide to Bolder Bets and Fewer Regrets: https://youtu.be/bbhZl3WRYdo?si=OQ1g_pgHtNXpPUUkBCG's Latest Insights for CEOs: https://on.bcg.com/3QQrlaSWho Wants to Be a CEO: https://lnk.to/so-what-Barton-CEOs09Chapters (0:00) Why CEO Stress Is Spiking (0:56) What Stress Does to Performance (1:41) What Factors Are Driving Stress (4:05) Why Companies Are Impacted Differently (4:44) Develop Your C-Suite for Higher Performance (5:49) Why Being CEO Feels Lonely (9:31) The Problem with Feedback at the Top (12:22) Rising Expectations from Employees (14:27) The CFO Dynamic Explained (17:37) How CEOs Navigate the Board (18:47) How Should CEOs Spend Their Time This podcast uses the following third-party services for analysis: Podtrac - https://analytics.podtrac.com/privacy-policy-gdrp

Send us Fan MailKunal ran the numbers. Modern pizza wins on absolute profit and payback period.Then he flagged it: you're projecting nearly 200 pizzas a day for a restaurant that hasn't opened yet. That's the instinct that separates good from great.This is a full McKinsey case in the restaurant industry, led by Mark Di Giorgio (ex-McKinsey Toronto). Kunal works through a New York pizza market entry question – modern vs. traditional.After the case, Mark breaks it down section by section with tactical detail you can apply immediately:Why catching volume risk after solving the math gets interviewers to lean forwardThe 4-step case opening most candidates skipHow to read an exhibit before touching the mathThe brainstorming close that turns a good answer greatCoaching with Mark:Join the Black Belt case prep program for personalized coaching with Mark and a prep strategy tailored to your goals and timelineConnect with Mark on LinkedInResources:Create a free account to access Case Interview Foundations – a 7-day case interview crash courseWatch more McKinsey, BCG, and Bain case interview demos on YouTubeFree Consulting Prep Just Got a Whole Lot BetterCreate a free MC account for access to step-by-step learning pathways, a brand new case prep course, and more. Download the MC app to prep anywhere.Connect With Management ConsultedCreate a free MC account or download the MC app (Apple, Android) to start your prep todaySchedule a free 15min consultation with the MC TeamWatch the video version of the podcast on YouTubeFollow us on LinkedIn, Instagram, and TikTokJoin an upcoming live event – case interviews demos, expert panels, and more

The promise of artificial intelligence is that it will take on all the boring tasks we don't want to do and free us up to do the fun, high-level work. But managing the AI tools can be its own kind of work. A new study from the Boston Consulting Group found that when workers have to closely monitor and manage their AI tools can cause cognitive exhaustion, which they dubbed “AI brain fry.”Marketplace's Stephanie Hughes spoke with Matt Kropp, managing director and senior partner at BCG and one of the co-authors of this new study.